慢性阻塞性肺病患者β2-AR基因多态性与复方薤白胶囊疗效的相关性研究  

Association Between β2-Adrenergic Receptor Gene Polymorphisms and Clinical Outcome in Patients with Chronic Obstructive Pulmonary Disease Treated with Compound Xiebai Capsule

作　　者：徐维国[1] 崔蓉[1] 岳崇梅 吴君华[1] 李丹[1] 谢佳俊 XU Weiguo;CUI Rong;YUE Chongmei;WU Junhua;LI Dan;XIE Jiajun(Mianyang Central Hospital, Mianyang, Sichuan 621000, China)

机构地区：[1]绵阳市中心医院,四川绵阳621000

出　　处：《湖南中医药大学学报》2018年第12期1440-1443,共4页Journal of Hunan University of Chinese Medicine

基　　金：四川省绵阳市卫生局科研计划(201314)

摘　　要：目的研究慢性阻塞性肺病(COPD)患者β2-肾上腺素受体(β2-AR)编码区16、27位点基因多态性与复方薤白胶囊疗效的相关性。方法选择2015年1月至2018年1月本院收治的COPD患者210例,均进行基因突变类型测序和复方薤白胶囊治疗,分别于治疗前、治疗第3天和第7天进行第1秒用力呼气量(FEV1)检测,并于治疗前、治疗第7天和第14天进行圣乔治呼吸问卷(SGRQ)调查及慢性阻塞性肺疾病评估测试(CAT)。结果 210例患者根据基因型分为野生型纯合子组97例、野生型与突变型基因杂合子组83例、突变型基因纯合子或杂合子组30例。治疗第3天和第7天,3组FEV1水平均显著升高且组间有差异(P<0.05),其中野生型纯合子组>野生型与突变型基因杂合子组>突变型基因纯合子或杂合子组(P<0.05)。治疗第7天和第14天,3组SGRQ评分及CAT评分均显著降低且组间有差异(P<0.05),其中野生型纯合子组低于野生型与突变型基因杂合子组及突变型基因纯合子或杂合子组(P<0.05)。结论β2-AR基因多态性会影响复方薤白胶囊疗效。Objective To investigate the association of the polymorphisms of loci16and27ofβ2-adrenergic receptor(β2-AR)coding region with the clinical outcome of patients with chronic obstructive pulmonary disease(COPD)treated with Compound Xiebai Capsule.Methods A total of210patients with COPD who were admitted to our hospital from January2015to January2018were enrolled and treated with Compound Xiebai Capsule.Gene mutation detection and sequencing were performed for all patients.Forced expiratory volume in1second(FEV1)was measured before treatment and on days3and7of treatment,and St.George's Respiratory Questionnaire(SGRQ)survey and COPD assessment test(CAT)were conducted before treatment and on days7and14of treatment.Results According to the genotype,210patients were divided into wild-type homozygote group with97patients,wild-mutant heterozygote group with83patients,and mutant homozygote/heterozygote group with30patients.On days3and7of treatment,the three groups had a significant increase in FEV1and there was a significant difference between these groups(P<0.05);the wild-type homozygote group had the highest FEV1,followed by the wild-mutant heterozygote group and the mutant homozygote/heterozygote group(P<0.05).On days7and14of treatment,the three groups had significant reductions in SGRQ and CAT scores and there were significant differences between these groups(P<0.05);the wild-type homozygote group had significantly lower scores than the wild-mutant heterozygote group and the mutant homozygote/heterozygote group(P<0.05).Conclusionβ2-AR gene polymorphisms will affect the clinical outcome of patients treated with Compound Xiebai Capsule.

关 键 词：慢性阻塞性肺病 β2-肾上腺素受体 基因多态性 复方薤白胶囊 

分 类 号：R256.1[医药卫生—中医内科学] R563.1[医药卫生—中医学]